Skip to content
Menu

Neurogene Inc. NGNE

Full chart Compare
Set alert

Price alert · NGNE

All alert types
22.93 USD -0.21 (-0.91%)

Regular-session close

23.50 +0.57 +2.49%

After hours · Nov 19, 5:15 PM ET

22.52 Day range 23.36
15.93 52-week range 43.66
YTD
+11.31%
1 year
+9.24%

5D -3.13 (-11.93%)

222426WedThuFriMonTue23.10
Market cap
474.67M
Revenue (ttm)
925.00K
EPS (ttm)
-5.03
Shares out
14.85M
Forward P/E
-4.85
YTD return
+11.31%
1-year return
+9.24%
50-day average
37.48
Volume
149.84K
Avg volume
309.99K
Open
23.22
Previous close
23.14
Day's range
22.52 – 23.36
52-week range
15.93 – 43.66
Analysts
Strong Buy
Price target
52.80 (+130.3%)

Key statistics

200-day average
37.96
Enterprise value
117.41M
Price / sales
361.33
Price / book
1.55
Free cash flow
-34.07M
Total cash
153.90M
Total debt
13.79M
Return on equity
-41.34%
Short % of float
7.87%

Fundamental scorecard

3 of 25 checks passed on NGNE’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NGNE Revenue — quarterly 0
NGNE Net income — quarterly -29.02M
NGNE EPS — quarterly -1.05

Earnings

NGNE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 18, 2024Sep 1, 2024-1.23-1.19+0.04+3.25%
Aug 9, 2024Jun 1, 2024-1.02-1.09-0.07-6.86%
May 10, 2024Mar 1, 2024-1.03-1.00+0.03+2.91%
Apr 2, 2024Dec 1, 2023-1.30———

Upgrades / downgrades

NGNE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 25, 2024HC Wainwright & Co.reitBuyBuy
Nov 20, 2024BMO CapitalmainOutperformOutperform
Nov 19, 2024HC Wainwright & Co.reitBuyBuy
Nov 12, 2024StifelmainBuyBuy
Nov 12, 2024BMO CapitalmainOutperformOutperform
Nov 12, 2024Leerink PartnersmainOutperformOutperform

About Neurogene Inc.

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on NGNE — it syncs with the Stock Master app.

Insider holders

NGNE insider holders
InsiderRelationLatest transactionDateShares held
BAKER BROS ADVISORS L.P.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityOct 4, 20230
COBB STUARTOfficerStock Award(Grant)Mar 12, 202420,391
CVIJIC CHRISTINE MIKAILPresidentPurchaseNov 21, 202476,844
MCMINN RACHEL L. PH.D.Chief Executive OfficerPurchaseNov 21, 20241,297,860
PATEL PRITIFormerSaleApr 2, 202337,313
SAMSARA BIOCAPITAL GP, LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseNov 25, 20240

Institution ownership

NGNE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.24%1,371,87930.87MSep 29, 2024
EcoR1 Capital, LLC8.56%1,271,34228.61MSep 29, 2024
Samsara BioCapital, LLC8.53%1,267,79028.53MSep 29, 2024
RTW Investments LP7.64%1,135,25625.54MSep 29, 2024
Great Point Partners LLC6.76%1,004,29122.60MSep 29, 2024
Redmile Group, LLC6.49%964,34721.70MSep 29, 2024

Fund ownership

NGNE fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.26%335,9777.56MSep 29, 2024
BlackRock Health Sciences Term Trust2.20%326,8777.35MSep 29, 2024
Fidelity Small Cap Growth Fund1.94%288,9226.50MAug 30, 2024
Blackrock Funds-Health Sciences Opportunity Portfolio1.91%284,0416.39MAug 30, 2024
Janus Henderson Global Life Sciences Fund1.87%278,1656.26MSep 29, 2024
iShares Russell 2000 ETF1.79%265,7555.98MOct 30, 2024